2301 E 60th St N
About SAB Biotherapeutics
Transforming the treatment of disease.
SAB Biotherapeutics, Inc. (SAB), is a biopharmaceutical company on the leading edge of innovation, developing and delivering natural technologies that have the potential to transform the prevention and treatment of diseases from Ebola to cancer, and diabetes to influenza. SAB’s first-of-its-kind therapeutic production platform holds the promise of treatment of rare conditions, long-term diseases and global pandemic threats.
A platform of promise.
Utilizing the most advanced antibody science in the world, SAB is delivering the world’s first large scale platform to create fully human, polyclonal antibodies.
The DiversitAb™ platform is diverse in its ability to produce antibodies for a variety of health conditions. The platform is also scalable and dynamic, enabling the production of large quantities of therapeutics with a shorter development cycle than current methods. The use of polyclonal antibodies enables the treatment to maintain effectiveness while responding to the evolving nature of disease.
Enhancing nature’s healing.
SAB’s innovative approach leverages the body’s natural ability to heal by generating fully human polyclonal antibodies to attack diseases. Fully human antibodies can be more effective, last longer, have fewer side effects than current technologies and provide immediate protection or passive immunity. Our technology uses a platform of genetically designed large animals to naturally produce human antibodies.
This natural, scalable technology can revolutionize the ability to create antibodies to prevent and treat human conditions such as cancer, autoimmune disorders, inflammation, and infectious diseases and emerging global health threats.
31 articles with SAB Biotherapeutics
SAB Biotherapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of SAB-185 for the Treatment of COVID-19
Phase 1b clinical trial will evaluate the safety and pharmacological activity of SAB-185 in COVID-19 patients Second study initiated this month testing SAB-185 for the treatment of COVID-19 SIOUX FALLS, S.D.--( BUSINESS WIRE )-- SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce targeted polyclonal antibodies, today announced the dosing of the first patient in its Phase 1b
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 21, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.
SAB Biotherapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of SAB-185 for the Treatment and Prevention of COVID-19
First participant dosed in Phase 1 study of SAB-185 for COVID-19 in healthy volunteers Phase 1b clinical trial evaluating the safety and pharmacological activity of SAB-185 in COVID-19 patients slated to start mid-August Novel proprietary technology platform leverages the native human immune response offering a differentiated high-potency therapeutic option to address virus mutations amidst ongoing pandemic
SAB Biotherapeutics Awarded $35.6M from U.S. Department of Defense for COVID-19 and Scaling Rapid Response Antibody Program
SAB Biotherapeutics Awarded $35.6M from U.S. Department of Defense for COVID-19 and Scaling Rapid Response Antibody Program Funds clinical development and manufacturing of SAB-185, a therapeutic candidate for COVID-19, as well as increased production capacity for rapid response JPEO-CBRND is also providing additional direct funding for first-in-human clinical studies in continued collaboration with BARDA, which remain on track
SAB Biotherapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of SAB-176 for Seasonal Influenza
SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce fully human polyclonal antibodies without the need for human donors, today announced that the first participant has been dosed in its Phase 1 clinical trial evaluating SAB-176 for the treatment of seasonal influenza. SAB-176 is a novel anti-influenza human immunoglobulin G (IgG) immunotherapy desig
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human plasma donors, today announced it has closed its Series B funding round at $14 million. New investor, global healthcare leader Merck, known as MSD outside the United States and Canada, was joined by South Dakota Equity Partners and several other foll
SAB Biotherapeutics President and CEO Eddie J. Sullivan, PhD, Featured on COVID-19 Panel at BIO Digital 2020
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human plasma donors, today announced Eddie J. Sullivan, PhD, President, CEO and Co-founder of SAB Biotherapeutics will serve an expert panelist during BIO Digital 2020 . The BIO International Convention, which has transitioned to a new and virtual event and
SAB Biotherapeutics Confirms Neutralizing Antibodies to SARS-CoV-2 and Begins Clinical Manufacturing of Novel COVID-19 Therapeutic Candidate
SAB-185 is a human polyclonal antibody therapeutic that potently neutralizes live SARS-CoV-2 at titers 4X higher than convalescent plasma Data suggests that SAB-185 may be an effective therapeutic against current and mutating strains of the virus On-track to initiate clinical trials for potential COVID-19 therapeutic in early summer 2020
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
SAB Biotherapeutics Advances Therapeutic for COVID-19 in Partnership with Department of Defense and BARDA
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human donors, announced today that it has been awarded expanded scope on their Rapid Response contract for their new therapeutic drug candidate to treat COVID-19,
COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB's novel platform technology, on-track for clinical evaluation as early as summer [08-April-2020] KING OF PRUSSIA, Pa. and SIOUX FALLS, S.D. , April 8, 2020 /PRNewswire/ -- Global biotherapeutics leader, CSL Behring and innova
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
SAB Biotherapeutics Awarded $27M Contract to Develop Novel Rapid Response Capability for U.S. Department of Defense
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company, advancing a new class of immunotherapies leveraging the native human immune response, announced today it has been awarded a contract from the U.S. Department of Defense (DoD) to develop and test a Rapid Response Antibody Program, valued at up to $27 million.
The collaborations will explore the possibility and the potential of new therapies to treat challenging autoimmune, infectious and idiopathic diseases by leveraging SAB’s DiversitAb™ platform.
SAB Biotherapeutics, Inc. announced today, that it has raised $22 million in its Series A-2 round that closed December 15, 2018.
SAB Biotherapeutics, Inc. has received a $10 million investment from T. Denny Sanford as part of its Series A-2 raise.
CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy
Promising new platform can rapidly respond to emerging infectious diseases
Results of the study were published today in The Lancet Infectious Diseases.
SAb Biotherapeutics announced today they have formed and officially launched a Utah-based wholly owned subsidiary, SAB Capra, LLC and incorporated the new entity under the SAB Biotherapeutics corporate umbrella.